Pre-clinical evaluation of a divalent liposomal vaccine to control invasive candidiasis
Candida albicans causes systemic infections with 20-50% mortality in critically ill and immunocompromised patients, despite antifungal treatment. Current therapies face limitations, including toxicity and resistance, underscoring the need for prophylactic vaccines. This study presents a novel divalent liposomal vaccine, delivering C. albicans Cht3 and Sap2 antigens. Vaccination induced protective Th1/Th17 immunity, a balanced Th1/Th2 ratio, antigen-specific antibodies, and boosted macrophage activity, improving survival in a mouse model of invasive candidiasis.
Authors
- Paula Sampaio (ORCID: https://orcid.org/0000-0002-1415-4428)
- Augusto Costa‐Barbosa (ORCID: https://orcid.org/0000-0002-5468-8491)
- Tony Collins (ORCID: https://orcid.org/0000-0002-4167-973X)
- Alexandra Correia (ORCID: https://orcid.org/0000-0003-0408-6262)
- Célia Pais (ORCID: https://orcid.org/0000-0001-5959-290X)
- Andreia C. Gomes (ORCID: https://orcid.org/0000-0002-0567-064X)
- Manuel Vilanova (ORCID: https://orcid.org/0000-0001-7007-306X)
- Maria Inês Pacheco (ORCID: https://orcid.org/0000-0002-7416-6965)
Institutions
- Universidade do Porto (PT)
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto (PT)
- University of Minho (PT)
Publication Details
- Journal
- npj Vaccines
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1038/s41541-025-01183-0
- Citations
- 4
- Primary Topic
- Immune responses and vaccinations
- Type
- article
- Field-Weighted Citation Impact
- 3.19
Funders
- Fundação para a Ciência e a Tecnologia